Literature DB >> 185294

Depression of macrophage function by a factor produced by neoplasms: a merchanism for abrogation of immune surveillance.

M C Pike, R Snyderman.   

Abstract

The possibility that macrophages mediate surveillance against the development of neoplasms has been reciving increasing support. The acquisition, by neoplastic cells, of the capacity to subvert macrophage function may be an important mechanism by which they escape destruction by the host and become established tumors. Indeed, animals implanted with syngeneic neoplasms developed depressed macrophage migratory ability in vivo and chemotactic responsiveness in virto. It therefore seemed plausible that neoplasms might be capable of producing inhibitors of macrophage function. The present report describes the identification of such a low molecular weight (6,000 to 10,000), heat-stable inhibitor of murine macrophage accumulation in vivo and chemotaxis in vitro. The inhibitor of macrophages was present in four different murine neoplasms, but not present in normal liver, spleen, or inflammatory exudate cells and did not affect PMN chemotaxis in vitro. When given with low numbers of neoplastic cells, the inhibitor increased both the frequency of tumor development and rate of tumor growth. By producing inhibitors of macrophage function, neoplasms may escape initial host surveillance mechanisms.

Entities:  

Mesh:

Year:  1976        PMID: 185294

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Beneficial effects of the thymic hormone preparation thymostimulin in patients with defects in cell-mediated immunity and chronic purulent rhinosinusitis. A double-blind cross-over trial on improvements in monocyte polarization and clinical effects.

Authors:  M Tas; J A Leezenberg; H A Drexhage
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

2.  Abnormal monocyte chemotaxis in patients with chronic purulent rhinosinusitis: an effect of retroviral p15E-related factors in serum.

Authors:  E M van de Plassche-Boers; M Tas; M de Haan-Meulman; M Kleingeld; H A Drexhage
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

3.  Inhibition of cytokine production by a tumor cell product.

Authors:  E Farram; M Nelson; D S Nelson; D K Moon
Journal:  Immunology       Date:  1982-07       Impact factor: 7.397

4.  Interaction of high or low metastatic related tumor lines with normal or lymphokine-activated syngeneic peritoneal macrophages: in vitro analysis of tumor cell binding and cytostasis.

Authors:  V Schirrmacher; B Appelhans
Journal:  Clin Exp Metastasis       Date:  1985 Jan-Mar       Impact factor: 5.150

5.  Successful tumour immunotherapy: possible role of antibodies to anti-inflammatory factors produced by neoplasms.

Authors:  M Nelson; D S Nelson; P B Spradbrow; V K Kuchroo; P A Jennings; G J Cianciolo; R Snyderman
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

6.  Alveolar macrophage dysfunction in malignant lung tumours.

Authors:  E Lemarie; P Carre; M F Legrand; M Lavandier; E Boissinot; M Renoux; G Renoux
Journal:  Thorax       Date:  1984-06       Impact factor: 9.139

7.  Effects of soluble mediators generated during growth of the Landschütz ascites carcinoma on the chemotaxis of normal and Corynebacterium parvum-stimulated peritoneal leucocytes.

Authors:  L C McIntosh; A W Thomson
Journal:  Br J Exp Pathol       Date:  1984-08

8.  Immunosuppressive activity of sera from gastric cancer patients.

Authors:  M Sakita; T Torii; S Imaki; M Kasuga; M Tamai; G Suzuki; M Kano; Y Fujita; S Majima
Journal:  Jpn J Surg       Date:  1984-03

9.  Macrophages and resistance to tumours. I. Inhibition of delayed-type hypersensitivity reactions by tumour cells and by soluble prducts affecting macrophages.

Authors:  M Nelson; D S Nelson
Journal:  Immunology       Date:  1978-02       Impact factor: 7.397

Review 10.  Effects of tumor growth on host defenses.

Authors:  G J Cianciolo; R Snyderman
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.